{"id":12016,"date":"2025-04-18T10:57:13","date_gmt":"2025-04-18T08:57:13","guid":{"rendered":"https:\/\/valintermed.com\/?p=12016"},"modified":"2025-04-18T10:57:13","modified_gmt":"2025-04-18T08:57:13","slug":"megalentsefalicheskaya-leykoentsefalopatiya-s-subkortikalnymi-kistami","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/megalentsofalicheskaya-leukopenia-with-subcortical-cysts\/","title":{"rendered":"Megalencephalic leukoencephalopathy with subcortical cysts"},"content":{"rendered":"<div class=\"fpm_start\"><\/div>\n<p>Megalencephalic leukoencephalopathy with subcortical cysts (MLLSC) is a rare genetic disorder characterized by myelination disorders and progressive neurological deficits. The underlying pathogenetic mechanism is abnormal development and degeneration of the white matter of the brain, leading to the formation of cysts in the subcortical areas. These cysts can lead to dysfunction of neurons, which manifests itself in the form of various neurological symptoms. The disease often has an asymptomatic onset and is detected in children and young adults, making its diagnosis and clinical observation particularly challenging.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-flat ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Content<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 eztoc-toggle-hide-by-default' ><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/megalentsofalicheskaya-leukopenia-with-subcortical-cysts\/#%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\" >History of the disease and interesting historical facts<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/megalentsofalicheskaya-leukopenia-with-subcortical-cysts\/#%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F\" >Epidemiology<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/megalentsofalicheskaya-leukopenia-with-subcortical-cysts\/#%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E\" >Genetic predisposition to this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/megalentsofalicheskaya-leukopenia-with-subcortical-cysts\/#%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Risk factors for the development of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/megalentsofalicheskaya-leukopenia-with-subcortical-cysts\/#%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Diagnosis of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/megalentsofalicheskaya-leukopenia-with-subcortical-cysts\/#%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\" >Treatment<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/megalentsofalicheskaya-leukopenia-with-subcortical-cysts\/#%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >List of medications used to treat this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/megalentsofalicheskaya-leukopenia-with-subcortical-cysts\/#%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Disease monitoring<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/megalentsofalicheskaya-leukopenia-with-subcortical-cysts\/#%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Age-related features of the disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/megalentsofalicheskaya-leukopenia-with-subcortical-cysts\/#%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\" >Questions and Answers<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\"><\/span>History of the disease and interesting historical facts<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Megalencephalic leukoencephalopathy with subcortical cysts was first described in the medical literature in the early 21st century, although similar neurological disorders had been observed earlier. Significant attention to this pathology began to appear after the discovery of a number of genetic mutations associated with the disease. An early study identified changes in myelination that reflect the specificity of the disease. <\/p>\n<p>An interesting fact is that some Arab countries report higher incidences of the disease, indicating a possible genetic predisposition in certain ethnic groups. Moreover, in some cases, a link to consanguine marriages has been noted, further highlighting the importance of genetics in such diseases.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F\"><\/span>Epidemiology<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>According to recent epidemiological studies, the prevalence of megalencephalic leukoencephalopathy with subcortical cysts varies and is approximately 1 in 100,000\u2013200,000 newborns. In most cases, the disease has an initial onset in childhood, but in some cases it can be detected in adult patients. Statistics also indicate a predominance of the disease in men.<\/p>\n<p>Various studies highlight the geographical dependence of cases. For example, in some regions of the Middle East and North Africa, there is an increase in the detection of cases, which may be due to specific environmental and genetic conditions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E\"><\/span>Genetic predisposition to this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>MLLSC is a hereditary disease that is often caused by mutations in genes responsible for myelination. The most studied are mutations in genes encoding proteins involved in the formation of myelin, such as the KIF1A and GJC2 genes. These genes play an important role in transport and intercellular interactions, which is critical for the normal functioning of neurons.<\/p>\n<p>Research shows that mutated versions of these genes can cause abnormalities in myelination processes, sometimes even in the absence of other clinical manifestations. This opens the door to understanding the disease mechanism and the possibility of early diagnosis through genetic testing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Risk factors for the development of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Risk factors for megalencephalic leukoencephalopathy include both genetic and environmental factors. The main risk factors include:<\/p>\n<ul>\n<li>Consanguinity (marriage between blood relatives)<\/li>\n<li>Presence of various diseases associated with myelination in the family<\/li>\n<li>Exposure to toxic chemicals in the environment<\/li>\n<li>Viral infections suffered by the mother during pregnancy<\/li>\n<\/ul>\n<p>These factors may create a predisposition to the development of this disease, which highlights the need for an integrated approach to prevention and monitoring of risk groups.<\/p><script data-noptimize=\"\" data-wpfc-render=\"false\">\nfpm_start( \"true\" );\n<\/script>\n\n<h2><span class=\"ez-toc-section\" id=\"%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Diagnosis of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Diagnosis of megalencephalic leukoencephalopathy is multidisciplinary and includes several methods:<\/p>\n<ul>\n<li><strong>Main symptoms:<\/strong> Common symptoms include progressive mental retardation, loss of coordination, spasticity, and epileptic seizures.<\/li>\n<li><strong>Laboratory tests:<\/strong> This may include a biochemical blood test and studies of the levels of various metabolites, which helps to exclude metabolic disorders.<\/li>\n<li><strong>Radiological examinations:<\/strong> Magnetic resonance imaging (MRI) is the primary imaging modality for detecting white matter changes and the presence of subcortical cysts.<\/li>\n<li><strong>Other types of diagnostics:<\/strong> Genetic testing can confirm the diagnosis based on the mutations identified.<\/li>\n<li><strong>Differential diagnosis:<\/strong> Includes exclusion of other forms of leukoencephalopathy, such as leukodystrophy, as well as tumor processes in the brain.<\/li>\n<\/ul>\n<p>These diagnostic measures not only allow us to confirm the diagnosis, but also to develop individualized treatment plans.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\"><\/span>Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Treatment of megalencephalic leukoencephalopathy is symptomatic, as there is currently no specific therapy. It includes:<\/p>\n<ul>\n<li><strong>General treatment:<\/strong> Comprehensive rehabilitation is carried out, aimed at improving the quality of life of patients. Includes sessions with a speech therapist and physiotherapist.<\/li>\n<li><strong>Pharmacological treatment:<\/strong> Antiepileptic drugs are used to control seizures, and muscle relaxants are used for spasticity.<\/li>\n<li><strong>Surgical treatment:<\/strong> It may be justified in cases of large cysts that cause compression of neurons, but the decision is always individual.<\/li>\n<li><strong>Other types of treatment:<\/strong> Alternative medicine methods are sometimes used, although their effectiveness is not always proven.<\/li>\n<\/ul>\n<p>It is important to note that treatment should be aimed at improving the patient&#039;s quality of life and functional capabilities.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>List of medications used to treat this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Currently, the following groups of drugs are used to treat MLS:<\/p>\n<ul>\n<li>Antiepileptic drugs (eg, lamotrigide, valproic acid)<\/li>\n<li>Muscle relaxants (eg, baclofen, tizanidine)<\/li>\n<li>Psychotropic drugs for the correction of emotional disorders<\/li>\n<li>Drugs to improve cerebral circulation<\/li>\n<\/ul>\n<p>Each prescription of medication must be subject to a thorough analysis of the patient&#039;s condition and his individual needs.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Disease monitoring<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Monitoring for megalencephalic leukoencephalopathy includes regularly scheduled visits to your doctor and monitoring for symptoms:<\/p>\n<ul>\n<li><strong>Control stages:<\/strong> Regular MRI to monitor disease progression and changes in white matter.<\/li>\n<li><strong>Forecast:<\/strong> The prognosis depends on the severity of the disease and the presence of relapses. In some cases, the disease can lead to severe disability.<\/li>\n<li><strong>Complications:<\/strong> There may be junctions or progression of neurological disorders, including mental disorders.<\/li>\n<\/ul>\n<p>It is necessary to continuously assess changes in the condition and adjust therapy according to the patient&#039;s needs.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Age-related features of the disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Megalencephalic leukoencephalopathy has different age-related manifestations. In childhood, the disease may manifest itself in the form of severe neurological disorders, while in adult cases, less pronounced symptoms are observed. However, in older age, progression of the disease may be observed, which leads to deterioration of the functional state. Different age groups require an individualized approach to the rehabilitation regimen and social support.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\"><\/span>Questions and Answers<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>What is megalencephalic leukoencephalopathy?<\/strong> It is a rare genetic disorder characterized by impaired myelination and the formation of cysts in the white matter of the brain.<\/li>\n<li><strong>What are the main symptoms of the disease?<\/strong> The main symptoms include progressive mental retardation, loss of coordination, spasticity and epileptic seizures.<\/li>\n<li><strong>How is MLLSC diagnosed?<\/strong> Diagnosis is based on MRI, clinical examination and genetic testing.<\/li>\n<li><strong>Is there an effective treatment for this disease?<\/strong> There is no specific treatment; therapy is aimed at symptomatic management and rehabilitation of the patient.<\/li>\n<li><strong>What is the prognosis for patients with this pathology?<\/strong> The prognosis depends on the severity of the disease and the initial age of onset; in some cases, a significant deterioration in the condition is possible.<\/li>\n<\/ul>\n<div class=\"fpm_end\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Megalencephalic leukoencephalopathy with subcortical cysts (MLESC) is a rare genetic disorder characterized by impaired myelination and progressive neurological deficits.<\/p>","protected":false},"author":1,"featured_media":20679,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[298],"tags":[],"class_list":["post-12016","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medlibrary"],"_links":{"self":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/12016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/comments?post=12016"}],"version-history":[{"count":1,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/12016\/revisions"}],"predecessor-version":[{"id":15128,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/12016\/revisions\/15128"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media\/20679"}],"wp:attachment":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media?parent=12016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/categories?post=12016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/tags?post=12016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}